what is glp-1 therapy UC Davis Health examines systemic impact of GLP-1–based therapies How GLP-1 Medications Boost Weight

Mild symptoms that are manageable and improving over time may not require any change in treatment

It is crucial to inform your healthcare provider if you suspect you have either of these allergies to ensure appropriate management and avoid potential triggers

The retatrutide availability timeline depends on ongoing clinical trials and regulatory review: Current status: Multiple phase 3 trials (TRIUMPH program) ongoing Phase 3 primary completion: Expected through mid-year NDA submission: Eli Lilly expected to submit to FDA in late future FDA review period: Approximately 10 months after submission Estimated approval: Potentially late next year at earliest Commercial launch: Could follow shortly after approval It is important to note that Eli Lilly has not announced an official filing timeline

Only 5% to 10% of patients discontinue treatment due to side effects